温德伯诺的临床前表征:药理动力学,安全性和增强认知功能的特性
Lyudmila Borets1, Tatyana Azhikina2, Eugene Zubkov3
1Federal Research Centre "Fundamentals of Biotechnology" of the Russian Academy of Sciences, Moscow 119071, Russia.
ACS pharmacology & translational science
|January 15, 2026
概括
维德伯诺尔在认知增强方面表现有前途,改善了小鼠的情节性记忆. 这种神经向药物调节基因表达的位置coeruleus,促进神经可塑性和减少神经炎症.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 认知障碍显著影响精神疾病患者.
- 维德伯诺尔 (Vindeburnol) 是一种eburnamine-vincamine类类衍生物,已经显示出潜力,但缺乏全面的表征.
- 了解它的机制对于开发新疗法至关重要.
研究的目的:
- 进行全面的临床前评估 vindeburnol.
- 评估其安全性,药理动力学,预认知效应和分子机制.
- 探索其作为神经变剂的潜力.
主要方法:
- 亚慢性毒性研究 (20和80毫克/公斤/天14天).
- 药物动力学分析 (口服剂量为40mg/kg).
- 行为测试 (新型物体识别) 和转录基因分析小鼠的脑部部位 (LC).
主要成果:
- 维登伯诺在20mg/kg时显示出良好的安全性;80mg/kg导致死亡率和肝毒性.
- 观察到高口服生物利用率 (75%) 和长半衰期 (7.58小时).
- 在没有运动障碍的情况下显著改善了情节性记忆;LC转录组学揭示了神经发生,突触可塑性和神经炎症基因的调节.
结论:
- 维德伯诺 (Vindeburnol) 是一种有前途的化合物,具有已证明的前认知效应.
- 它的机制涉及促进神经可塑性和通过LC转录调制抵消病理过程.
- 进一步调查作为一种潜在的神经变剂是有必要的.
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
558
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
558
Drug Abuse and Addiction: Pharmacological Phenomena
1.1K
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
1.1K
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
779
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
779
Preclinical Development: Overview
5.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.8K
CNS Depressants: Alcohol and Nicotine
1.0K
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
1.0K
CNS Stimulants: Psychedelic Agents
686
Hallucinogens, also known as psychedelic drugs, are a class of substances known for their ability to alter perception, cognition, and emotions. Despite their profound effects on the mind, these drugs are non-addictive, setting them apart from many other abused substances. The mechanism of action of these drugs lies in their impact on the 5-HT2A receptor in the brain. Upon activation, this receptor couples to Gq-type G proteins, triggering a cascade that releases intracellular calcium. This...
686


